Keywords: Myrexis, EpiCept, Azixa, License termination, Glioblastoma multiform

Myrexis returns rights to Azixa to EpiCept

Article | 06 September 2012

Print This

US drug developer EpiCept (Nasdaq: EPCT) says it has received notice of termination, effective as of August 28, 2012, of its license ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in